Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMC

Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices

Sharma RR., Pollock K., Hubel A., McKenna D.

Clinical Trial on Immune Modulation, published in Transfusion (2014) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Transfusion (2014)
Reported sample size
—
Source database
Europe PMC
PMID
24898458
PMCID
PMC6364749
DOI
10.1111/trf.12421
Citations
299

Abstract (original English)

Mesenchymal stem cells (MSCs) have recently generated great interest in the fields of regenerative medicine and immunotherapy due to their unique biologic properties. In this review we attempt to provide an overview of the current clinical status of MSC therapy, primarily focusing on immunomodulatory and regenerative or tissue repair applications of MSCs. In addition, current manufacturing is reviewed with attention to variation in practices (e.g., starting material, approach to culture and product testing). There is considerable variation among the 218 clinical trials assessed here; variations include proposed mechanisms of action, optimal dosing strategy, and route of administration. To ensure the greatest likelihood of success in clinical trials as the field progresses, attention must be given to the optimization of MSC culture.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Mesenchymal Stem CellsFetal BloodHumansGraft vs Host DiseaseGenomic InstabilityMesenchymal Stem Cell TransplantationCell SeparationRegenerationHematopoiesisQuality Control

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research